quinazolines has been researched along with Leukemia, Promyelocytic, Acute in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Yu, K; Zhang, T; Zhang, Z | 1 |
| Chen, M; Gan, L; Li, L; Liu, B; Liu, L; Shan, Z; Xiao, C; Xu, T; Yao, S; Zhao, Y; Zhong, L | 1 |
| Baksiene, S; Borutinskaite, V; Navakauskiene, R; Vitkeviciene, A | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Navakauskiene, R; Savickiene, J; Stirblyte, I; Treigyte, G; Valiuliene, G | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Yousefi, M; Zaghal, A; Zaker, F; Zekri, A | 1 |
| Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH | 1 |
| Matsuo, K; Tanimoto, M; Uchida, A | 1 |
| Fujiwara, Y; Hotta, K; Ishimaru, F; Kiura, K; Kubonishi, S; Matsuo, K; Nakajima, H; Niiya, D; Ogino, A; Shinagawa, K; Tabata, M; Tanimoto, M; Uchida, A; Ueoka, H | 1 |
| Kiyoi, H | 1 |
| Ennishi, D; Hatake, K; Hino, N; Senoo, T; Sezaki, N; Terui, Y | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Aonuma, S; Nagao, M; Nakayasu, M; Shima, H; Sugimura, T | 1 |
13 other study(ies) available for quinazolines and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers, Tumor; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis; Quinazolines; Retinoic Acid Receptor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
[Mechanism underlying inhibition of proliferation and promotion of apoptosis by lapatinib in HL60 cells].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspase 9; Cell Proliferation; Cell Survival; HL-60 Cells; Humans; Lapatinib; Leukemia, Promyelocytic, Acute; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2017 |
Epigallocatechin-3-gallate and BIX-01294 have different impact on epigenetics and senescence modulation in acute and chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Azepines; Catechin; Cellular Senescence; Chromobox Protein Homolog 5; Drug Screening Assays, Antitumor; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Quinazolines | 2018 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
Topics: Azepines; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Quinazolines; Tretinoin | 2014 |
Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Topics: Adult; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines | 2010 |
APL during gefitinib treatment for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines | 2005 |
Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
[The present status of, and problems with the development of FLT3 kinase inhibitors].
Topics: Adult; Cell Cycle Proteins; Chaperonins; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Mutation; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Staurosporine | 2006 |
A case of acute promyelocytic leukemia during gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines; Remission Induction; Tretinoin | 2006 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
Loss of the MYC gene amplified in human HL-60 cells after treatment with inhibitors of poly(ADP-ribose) polymerase or with dimethyl sulfoxide.
Topics: Benzamides; Blotting, Southern; Cell Differentiation; Cell Line; Coumarins; Dimethyl Sulfoxide; Gene Amplification; Humans; Leukemia, Promyelocytic, Acute; Niacinamide; Nucleic Acid Hybridization; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; Quinazolines; Quinazolinones; RNA, Neoplasm | 1989 |